INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50801, 2419, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50802, 2420, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50803, 13565, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50804, 13566, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50805, 16172, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50806, 16174, 'Everolimus', 'Hyperglycemia', 'Elevations in serum blood glucose levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting serum glucose levels is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of glucose levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50807, 2361, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50808, 2419, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50809, 2420, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50810, 13565, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50811, 13566, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50812, 16172, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50813, 16174, 'Everolimus', 'Hypercholesterolemia', 'Elevations in cholesterol and triglyceride levels have been reported in patients taking inhibitors of mTOR (mammalian target of rapamycin).  Monitoring of fasting lipid profile is recommended prior to the start of therapy and periodically thereafter.  Clinicians should achieve control of lipid levels before initiating therapy with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50814, 2361, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50815, 2419, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50816, 2420, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50817, 13565, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50818, 13566, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50819, 16172, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50820, 16174, 'Everolimus', 'Infections', 'The immunosuppressant effect of inhibitors of mTOR (mammalian target of rapamycin) may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of viral infections.  Therapy with these agents should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection.  It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50821, 2361, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50822, 2419, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50823, 2420, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50824, 13565, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50825, 13566, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50826, 16172, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50827, 16174, 'Everolimus', 'Wounds and Injuries', 'Inhibition of mTOR activity results in delays of wound healing and increases the occurrence of wound-related complications, which might require surgical intervention.  Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes).  Caution is recommended when using these agents, particularly in the perioperative period.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50828, 958, 'Exemestane', 'Osteoporosis', 'Reductions in bone mineral density (BMD) over time are seen with the use of exemestane.  Women with osteoporosis or at risk of osteoporosis should have their BMD formally assessed by densitometry at treatment initiation.  Monitoring for BMD loss is recommended, and treatment for it should be started as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50829, 958, 'Exemestane', 'Vitamin D Deficiency', 'Routine assessment of vitamin D levels prior to the start of aromatase inhibitor treatment should be performed, due to the high prevalence of vitamin D deficiency in women with early breast cancer.  Women with vitamin D deficiency should receive supplementation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50830, 15591, 'Exenatide', 'Kidney Failure, Chronic', 'Exenatide should not be used in patients with severe renal impairment (CrCl <30 mL/min) or end-stage renal disease, and should be used with caution in patients with moderate renal impairment and renal transplantation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50831, 15592, 'Exenatide', 'Kidney Failure, Chronic', 'Exenatide should not be used in patients with severe renal impairment (CrCl <30 mL/min) or end-stage renal disease, and should be used with caution in patients with moderate renal impairment and renal transplantation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50832, 15591, 'Exenatide', 'Pancreatitis', 'The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis.  Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk.  Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis.  If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated.  Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50833, 15592, 'Exenatide', 'Pancreatitis', 'The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis.  Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk.  Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis.  If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated.  Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50834, 15591, 'Exenatide', 'Thyroid Neoplasms', 'GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).  Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50835, 15592, 'Exenatide', 'Thyroid Neoplasms', 'GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).  Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50836, 15591, 'Exenatide', 'Kidney Diseases', 'There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.  Some of these events occurred in patients without known underlying renal disease.  These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation.  Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration.  The frequency of gastrointestinal events is increased as renal function declines.  There is limited clinical experience with most of these drugs in patients with severe renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50837, 15592, 'Exenatide', 'Kidney Diseases', 'There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.  Some of these events occurred in patients without known underlying renal disease.  These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation.  Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration.  The frequency of gastrointestinal events is increased as renal function declines.  There is limited clinical experience with most of these drugs in patients with severe renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50838, 0, 'Ethotoin', 'Hematologic Diseases', 'Hematologic toxicities have been associated with the use of hydantoin anticonvulsants, particularly mephenytoin.  Thrombocytopenia, leukopenia, neutropenia, agranulocytosis, pancytopenia and, rarely, hemolytic anemia, aplastic anemia and pure red cell aplasia have been reported.  Therapy with hydantoin anticonvulsants should be administered cautiously in patients with preexisting blood dyscrasias and/or bone marrow depression.  Complete blood counts, including platelets, should be performed prior to initiating therapy and regularly for several months thereafter.  For mephenytoin, the manufacturer recommends performing counts after 2 weeks on a low dosage, after another 2 weeks when full dosage is reached, then monthly for a year, and every 3 months thereafter.  Marked depression of blood counts may be indication for withdrawal of hydantoin therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50839, 0, 'Ethotoin', 'Liver Diseases', 'Hydantoin anticonvulsants are primarily metabolized by the liver.  Both metabolic activity and plasma protein binding may be significantly altered in patients with liver disease, resulting in elevated drug levels (total and unbound fraction) and increased risk of toxicity.  Therapy with hydantoin anticonvulsants should be administered cautiously in patients with impaired hepatic function.  Reduced dosages and slower titration may be necessary.  In addition, periodic monitoring of liver function is recommended, since the use of anticonvulsants, including hydantoins, has been associated with hepatotoxicity related to drug hypersensitivity.  Hepatic failure and death have occurred.  Hydantoin therapy should be discontinued and not readministered if evidence of liver damage is observed and felt to be drug-related.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50840, 0, 'Ethotoin', 'Porphyrias', 'The use of phenytoin has rarely been associated with exacerbation of porphyria.  Therapy with phenytoin should be administered cautiously in patients with porphyria.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50841, 0, 'Ethotoin', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50842, 0, 'Ethotoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50843, 0, 'Ethotoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50844, 0, 'Ethotoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50845, 20757, 'Etonogestrel', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50846, 20757, 'Etonogestrel', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50847, 20757, 'Etonogestrel', 'Breast Neoplasms', 'The use of progestogens is considered by manufacturers to be contraindicated in patients with existing or suspected malignancy of the breast.  Some supportive data are available for medroxyprogesterone.  Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly.  A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate.  The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years.  Thus, an increased risk (approximately 2-fold) is associated with intramuscular medroxyprogesterone use in the first 5 years.  A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50848, 20757, 'Etonogestrel', 'Liver Diseases', 'The use of progestogens, in general, is contraindicated in patients with impaired hepatic function or liver disease.  There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease.  However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver.  Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50849, 20757, 'Etonogestrel', 'Thromboembolism', 'The use of progestogens, in general, is considered by manufacturers to be contraindicated in patients with active thrombophlebitis, cerebrovascular disease, or a current or past history of thromboembolic disorders.  While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant.  Medroxyprogesterone, a common progestational agent, has been shown to produce a hypercoagulable state in high dosages.  Whether or not this effect contributes to the development of thrombotic events is unknown.  However, thrombophlebitis and pulmonary embolism have been reported with megestrol, an antineoplastic and progestational agent.  In addition, an increased risk of nonfatal venous thrombosis has been associated with oral contraceptive combinations containing desogestrel or gestodene relative to those that contain other progestins (e.g., levonorgestrel, norethindrone), suggesting some degree of hemostatic effect by progestogens.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50850, 20757, 'Etonogestrel', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50851, 20757, 'Etonogestrel', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50852, 20757, 'Etonogestrel', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50853, 20757, 'Etonogestrel', 'Gallbladder Diseases', 'Etonogestrel might increase the risk of gallbladder disease.  Caution and monitoring of symptoms is suggested in patients with history or active gallbladder disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50854, 0, 'Ezogabine', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50855, 0, 'Ezogabine', 'Alcoholism', 'The use ezogabine with alcohol increases the systemic exposure to ezogabine.  Patients should be advised of possible worsening of dose-related adverse reactions if they take ezogabine with alcohol.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50856, 0, 'Ezogabine', 'Hepatic Insufficiency', 'No dosage adjustment is recommended in patients with mild hepatic impairment.  Dosage adjustment is recommended in patients with moderate or severe hepatic impairment.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50857, 0, 'Ezogabine', 'Hyperbilirubinemia', 'Ezogabine has been shown to interfere with clinical laboratory assays of both serum and urine bilirubin, which can result in falsely elevated readings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50858, 0, 'Ezogabine', 'Long QT Syndrome', 'QT prolongation was observed in patients treated with ezogabine.  It is recommended to monitor the QT interval when ezogabine is used with medicines known to increase QT interval and in patients with known prolonged QT interval, congestive heart failure, ventricular hypertrophy, hypokalemia, or hypomagnesemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50859, 0, 'Ezogabine', 'Kidney Diseases', 'Dosage adjustment is recommended in patients with creatinine clearance <50 mL/min or patients with end-stage renal disease receiving hemodialysis.  A supplemental dose is recommended immediately following hemodialysis.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50860, 0, 'Ezogabine', 'Retinal Diseases', 'The use of ezogabine can cause abnormalities of the retina.  Patients should have baseline ophthalmologic testing by an ophthalmic professional and follow-up testing as clinically indicated.  Patients who cannot be monitored should not be treated with ezogabine.  The ophthalmologic monitoring program should include visual acuity testing, dilated fundus photography, and optical coherence tomography.  Additional testing may include fluorescein angiograms, perimetry, and electroretinograms.  If retinal pigmentary abnormalities or vision changes are detected, ezogabine should be discontinued unless no other suitable treatment options are available and the benefits of treatment outweigh the potential risk of vision loss.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50861, 0, 'Ezogabine', 'Urinary Retention', 'The use of ezogabine may cause urinary retention.  A comprehensive evaluation of urologic symptoms should be conducted prior to and during treatment with ezogabine as clinically indicated.  It is recommended to monitor closely for urologic symptoms in patients at risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50862, 4450, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50863, 12215, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50864, 18486, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50865, 18617, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50866, 18618, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50867, 18619, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50868, 18620, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50869, 18621, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50870, 19524, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50871, 21635, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50872, 21636, 'Etoposide', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50873, 4450, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50874, 12215, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50875, 18486, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50876, 18617, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50877, 18618, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50878, 18619, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50879, 18620, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50880, 18621, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50881, 19524, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50882, 21635, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50883, 21636, 'Etoposide', 'Bone Marrow Failure Disorders', 'Etoposide induces dose-related myelosuppression.  Leukopenia, thrombocytopenia, and anemia have been reported during etoposide therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy should be administered cautiously in patients whose bone marrow reserve may be severely depressed and should be withheld if an absolute neutrophil counts fall below 500/mm3 and/or platelet counts fall below 50,000/mm3.  Clinical monitoring of hematopoetic function is recommended.  Periodic complete blood counts should be done during the course of etoposide treatment and it should be performed prior to each cycle of therapy and at appropriate intervals during and after therapy.  At least one determination should be done prior to each dose.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50884, 4450, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50885, 12215, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50886, 18486, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50887, 18617, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50888, 18618, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50889, 18619, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50890, 18620, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50891, 18621, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50892, 19524, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50893, 21635, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50894, 21636, 'Etoposide', 'Kidney Diseases', 'Etoposide is primarily eliminated by the kidney.  Less than 50% is eliminated as unchanged drug in the urine.  Reduced clearance, increased AUC, and decreased volume of distribution have been noted in patients with impaired renal function.  Therapy should be administered cautiously and dosages reduced in patients with compromised renal function.  Patients with a creatinine clearance between 15 to 50 mL/min should receive 75% of the recommended dosage of etoposide.  Data are not available in patients with creatinine clearances <15 mL/min and further dosage reductions are recommended.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50895, 2521, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50896, 16268, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50897, 16274, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50898, 18760, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50899, 18761, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (50900, 22080, 'Ezetimibe', 'Liver Diseases', 'Ezetimibe is partially metabolized in the liver.  After a single 10 mg dose, the mean area under the plasma concentration-time curve (AUC) for total ezetimibe was increased approximately 1.7-fold, 3- to 4-fold, and 5- to 6-fold, in patients with mild (Child-Pugh score 5 to 6), moderate (Child-Pugh score 7 to 9), and severe hepatic impairment (Child-Pugh score 10 to 15), respectively, compared to healthy subjects.  Due to the unknown effects of increased exposure to ezetimibe in patients with moderate or severe hepatic impairment, therapy with ezetimibe is not recommended in these patients.  The combination of ezetimibe with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels.', '3', '', 'DDInter', 0);
